Group 1: Core Insights - The article highlights the risks and challenges associated with the contribution of intangible assets in the process of overseas listing for companies [2] - It emphasizes the need for companies to be aware of the potential legal and tax implications arising from the overvaluation of intangible assets [4][8] Group 2: Assessment Risks - There is a risk of inflated valuations of intangible assets, which can lead to legal liabilities for shareholders if the actual value is lower than the assessed value [5] - Assessment institutions may also face legal consequences if their evaluations are found to be inaccurate, as they are responsible for the accuracy of their reports [6] Group 3: Tax Risks - Personal income tax implications arise when shareholders contribute intangible assets, with a 20% tax on capital gains from the transfer of such assets [8] - Corporate income tax benefits can be affected by the overvaluation of intangible assets, leading to potential tax liabilities and penalties if discrepancies are identified by tax authorities [9] - Value-added tax (VAT) treatment varies based on the classification of intangible assets, with potential exemptions for technology-related assets if conditions are met [10] Group 4: Recommendations - Companies are advised to select reputable assessment institutions and establish internal review mechanisms to ensure fair valuations of intangible assets [12] - It is recommended to include liability clauses in contracts with assessment institutions to mitigate risks associated with inaccurate evaluations [12]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Hainan Drinda New Energy Technology Co., Ltd. 海南鈞達新能源科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：02865） 有關認購理財產品的須予披露交易 認購理財產品 董事會宣佈，於2025年1月24日、2025年2月28日、2025年3月11日、2025年 司滁州捷泰利用其閒置資金認購若干該等理財產品，包括認購第一項興業銀行 理財產品、第十四項興業銀行理財產品、第十五項興業銀行理財產品、第二項 興業銀行理財產品、第三項興業銀行理財產品、第四項興業銀行理財產品及第 十一項興業銀行理財產品，認購金額分別為人民幣30百萬元、人民幣100百萬 元、人民幣100百萬元、人民幣50百萬元、人民幣100百萬元、人民幣100百萬 元及人民幣100百萬元。 董事會宣佈，於2025年4月30日、2025年5月7日、2025年6月5日及2025年7月3 ...

Group 1 - The report details the specialized training conducted for the management and actual controller of Guangdong Zhongqi New Materials Co., Ltd. following a recent change in the actual controller [1] - The training covered compliance requirements for the use of raised funds, operational norms for listed companies, behavior norms for actual controllers, and information disclosure [1] - The training was well-received, with participants actively engaging and enhancing their understanding of relevant laws and regulations, which will help improve corporate governance and operational standards [1]

Core Insights - In the first half of 2025, 55 listed companies in the cultural tourism sector were analyzed, with 31 experiencing an increase in market value and 24 seeing a decline [3][18] - The highest market value increases were recorded by Wanda Hotel Development at 173.65%, Feiyang Group at 140.7%, and Jinma Amusement at 92.68% [3][4] - Conversely, the largest declines were seen in Lujing Technology at -48.03%, Lingnan Holdings at -43.34%, and Yingxin Development at -26.03% [6][7] Market Value Changes - As of June 30, 2025, the total market value of Wanda Hotel Development was 2.699 billion, while Feiyang Group and Jinma Amusement had market values of 0.126 billion and 4.521 billion respectively [4][7] - Ctrip led the market with a total value of 274.37 billion, followed by China Duty Free at 124.57 billion and Huazhu at 74.53 billion [8][9] - The overall market value of the remaining 52 companies was 390 billion, indicating a significant concentration of value among the top three companies [8] Sector Performance - The cultural tourism sector showed a mixed performance, with scenic area companies generally performing well, such as Haichang Ocean Park with a 39.1% increase and Zhangjiajie with a 28.55% increase [12][13] - Hotel companies also showed varied results, with Huazhu leading at 745.31 billion, while Atour saw a 20.41% increase [14][15] - Online travel companies experienced declines, with Ctrip and Tuniu dropping by 14.94% and 17.79% respectively, while Tongcheng saw a modest increase of 6.08% [16][17] Company-Specific Developments - Wanda Hotel Development's significant increase in market value was attributed to the sale of its subsidiary Wanda Hotel Management for 2.5 billion, which is expected to improve its financial structure [6][7] - Lujing Technology's decline was linked to negative media coverage regarding its management capabilities in scenic area operations [7][8] - The overall performance of cultural tourism companies reflects ongoing operational pressures, with some companies like Fosun Tourism Culture delisting from the Hong Kong stock market [18][19]

Group 1 - On July 9, Lens Technology and Peak Technology were listed on the Hong Kong Stock Exchange, marking the addition of 10 A-share companies to the "A+H" camp this year [1] - Both companies saw significant stock price increases on their first trading day, with Lens Technology closing up 9.13% and Peak Technology up 16.02% [1] - Lens Technology's A-shares traded at a premium of 25.49% over H-shares, while Peak Technology's A-shares had a premium of 43.04% over H-shares at the close of the first trading day [1] Group 2 - Lens Technology issued 262 million shares at an IPO price of HKD 18.18 per share, raising HKD 4.768 billion, with a subscription rate of 462.76 times for the public offering and 16.68 times for the international offering [1] - The company is positioned as a one-stop precision manufacturing solution provider for the entire industrial chain of smart terminals, with a leading revenue ranking in related industries expected in 2024 [1] - Peak Technology's IPO price was HKD 120.5, raising HKD 2.259 billion, with cornerstone investors including Taikang Life, collectively subscribing for USD 112 million [1] Group 3 - As of July 9, among 160 A+H stocks, only 3 had price inversions, all of which are leading companies [1] - Notable companies like Hengrui Medicine and CATL, which went public in Hong Kong this year, have seen H-shares increase by 58% and 46.39% respectively, while their A-shares are trading at discounts of 9.83% and 22.82% [1] - According to KPMG, the trend of A+H listings is expected to rise, with 47 new listing applications in the first half of 2025, significantly exceeding the total for 2024 [1] Group 4 - CICC predicts that A+H listings will generate an increase in quality assets, estimating that if companies queued for listing by the end of June go public within the year, approximately HKD 340 billion in new financing could be raised, enhancing the total market capitalization of Hong Kong stocks by 0.8% [1]

Group 1 - The event "Changsha Capital Market Lecture" focused on enhancing companies' understanding of the Hong Kong capital market and expanding their financing channels [1][3] - Experts from various organizations provided in-depth insights on overseas listings, including the latest policy dynamics, legal compliance, and financial management considerations [3] - The event highlighted successful cases of companies from Changsha, such as MicroStep Information listed on NASDAQ and Lens Technology listed on Hong Kong Stock Exchange, indicating a positive trend in overseas listings [3] Group 2 - The Changsha government has been improving its enterprise listing service system by establishing a reserve enterprise database and providing targeted training and one-on-one guidance [3][4] - The event was co-hosted by the Changsha Municipal Financial Office and the Hong Kong Stock Exchange, with support from various local institutions [4]

证券代码：605389 证券简称：长龄液压 公告编号：2025-027 江苏长龄液压股份有限公司 关于控股股东协议转让股份暨控制权拟发生变更的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 本次权益变动前，夏继发持有江苏长龄液压股份有限公司（以下简称"长 龄液压""公司"或"上市公司"）58,800,000 股股份，均为无限售条件流通股， 占上市公司股份总数的 40.81%。夏泽民持有长龄液压 39,200,000 股股份，均为 无限售条件流通股，占上市公司股份总数的 27.21%。夏继发为公司控股股东， 夏继发、夏泽民为公司实际控制人。 江阴澜海浩龙企业管理合伙企业（有限合伙）（以下简称"澜海浩龙"）系 由夏继发担任执行事务合伙人的企业，为夏继发、夏泽民的一致行动人，持有长 龄液压 4,200,000 股股份，均为无限售条件流通股，占上市公司股份总数的 2.91%。 ? 交易方案 此外，根据《股份转让协议》的约定，无锡核芯破浪科技合伙企业（有限合 伙）（以下简称"核芯破浪"）拟按照《上市公司收 ...

Core Viewpoint - Grandway Law Offices has issued a legal opinion regarding the application of Hanhigh Group Co., Ltd. for the initial public offering (IPO) of its shares on the main board, confirming that the company meets the necessary legal and regulatory requirements for the IPO [2][24]. Group 1: Company Background - Hanhigh Group Co., Ltd. was established on September 30, 2020, as a joint-stock company, evolving from Foshan Shunde Hanhigh Hardware Products Co., Ltd., which was founded on September 13, 2004 [1][2]. - The company operates in the home hardware and outdoor furniture sectors, focusing on research, design, production, and sales [8][10]. Group 2: Legal Compliance and Approval - The legal opinion confirms that the company has obtained the necessary approvals from its shareholders for the IPO, and the resolutions made during the 2022 first extraordinary general meeting are deemed legal and effective [5][6]. - The company has been operating for over three years and has a sound organizational structure, fulfilling the requirements set forth in the relevant regulations [6][10]. Group 3: Financial Health - Hanhigh Group's financial reports for the last three years have received unqualified audit opinions, indicating a stable financial condition [6][10]. - The company's revenue for 2019, 2020, and 2021 was reported as 802.48 million, 853.14 million, and 1.47 billion respectively, with a cumulative revenue exceeding 1 billion over the last three years [10][24]. Group 4: Shareholder Structure and Independence - The actual controllers of Hanhigh Group, siblings Ou Jinfeng and Ou Jinli, have remained unchanged over the past three years, ensuring stability in ownership [8][10]. - The company maintains independence from its controlling shareholders, with no significant adverse effects from related party transactions [15][16]. Group 5: Regulatory Compliance - The company has complied with the relevant laws and regulations, including the Company Law and Securities Law, and has no significant legal disputes that could hinder the IPO process [9][22]. - Hanhigh Group has disclosed all related party transactions in its prospectus, ensuring transparency and compliance with regulatory requirements [15][22].

Core Viewpoint - The company Sihuan Pharmaceutical (00460.HK) is pursuing the independent listing of its subsidiary Xuan Zhu Bio-Tech, which has faced challenges in its previous attempts to list on the STAR Market and is now targeting the Hong Kong Stock Exchange for its IPO [1][4]. Group 1: Listing Attempts - Sihuan Pharmaceutical initially planned to spin off Xuan Zhu Bio-Tech for a listing on the STAR Market in March 2022, but the IPO was halted in March 2023 and ultimately withdrawn in May 2024 due to strategic considerations and market conditions [4]. - Following the withdrawal from the A-share market, Sihuan Pharmaceutical initiated a new plan to list Xuan Zhu Bio-Tech on the Hong Kong Stock Exchange, with a second application submitted in June 2024 [4]. Group 2: Product Development - Xuan Zhu Bio-Tech has successfully launched its core product KBP-3571, which is used for treating duodenal ulcers and is expanding its indications to include gastroesophageal reflux disease [6][8]. - The company has over ten drug assets in active development, targeting diseases such as digestive system disorders, tumors, and non-alcoholic fatty liver disease [6]. Group 3: Financial Performance - Despite the launch of KBP-3571, Xuan Zhu Bio-Tech reported continuous losses, with projected losses increasing in 2024. Revenue figures for 2023 and 2024 show a significant decline, with losses reported at 300 million yuan for 2023 and 556 million yuan for 2024 [9]. - The company's R&D expenditures have decreased in 2024, with a notable drop in the proportion of R&D spending relative to total operating expenses, attributed to increased administrative and sales expenses [10]. Group 4: Future Outlook - Xuan Zhu Bio-Tech plans to continue investing heavily in the clinical development of its core products, particularly KBP-3571, which is entering Phase III trials, and other products targeting breast cancer and lung cancer [11].

Group 1 - Hunan Chuyuan New Materials Co., Ltd. has received approval for its IPO application on the ChiNext board, aiming to become the first listed company in Loudi City, Hunan Province [1][3] - The company, established in 2017, specializes in electronic information new materials and has achieved a 13.2% global market share in the photosensitive dry film sector, ranking third worldwide [2] - Revenue figures for the company show a fluctuating upward trend, with revenues of 910 million yuan, 890 million yuan, and 1.057 billion yuan from 2022 to 2024, alongside net profits of 160 million yuan, 155 million yuan, and 170 million yuan respectively [2] Group 2 - The IPO aims to raise 1.22 billion yuan for the construction of high-end photosensitive dry film projects and a research and operation center [2] - Loudi City has been historically silent in terms of capital market presence, lacking listed companies which hampers regional industrial upgrades and talent attraction [3][4] - The company represents a significant opportunity for Loudi City to break its silence in the capital market, as it is the only company from the city currently pursuing an IPO [4]